Digest Network Come funziona
Network
/
Società
Bi
Non verificato

Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

16 comunicati stampa

Guarda tutti i comunicati
05/12/2025
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance
Fonte
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Emittente
Business Wire
1.00
0
05/12/2025
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Oncologia
Mercato del lavoro
Industria
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance
Fonte
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Emittente
Business Wire
1.00
0
16/09/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Mercato del lavoro
Industria
Biocytogen Announces ADC Innovator Tubulis Has Signed Global Exclusive License Agreement for Single Antibody
Fonte
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Emittente
Business Wire
1.00
0
16/09/2025
Biocytogen Announces ADC Innovator Tubulis Has Signed Global Exclusive License Agreement for Single Antibody
Fonte
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Emittente
Business Wire
1.00
0
04/09/2025
Biocytogen Enters into Agreement with Merck to Advance Antibody-Conjugated Lipid-Based Delivery Solutions
Fonte
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Emittente
Business Wire
1.00
0
04/09/2025
Biocytogen Enters into Agreement with Merck, KGaA, Darmstadt, Germany to Advance Antibody-Conjugated Lipid-Based Delivery Solutions
Fonte
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Emittente
Business Wire
1.00
0
10/07/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
Mercato del lavoro
Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development
Fonte
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Emittente
Business Wire
1.00
0
10/07/2025
Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development
Fonte
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Emittente
Business Wire
1.00
0
05/06/2025
Industria
Scienza
Attrezzature medico-sanitarie
Biotecnologia
Medicina - Varie
Sanità
Farmaceutica
Salute
Biocytogen Secures Japan Patent for RenMab Platform, Expands Global Patent Portfolio for RenMice Fully Human Antibody/TCR Platform
Fonte
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Emittente
Business Wire
1.00
0
04/06/2025
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Ottica
Biotecnologia
Biocytogen and Nanjing Chia Tai Tianqing Announce IND Approval in China for Co-Developed Anti-IGF-1R Antibody NTB003 (BCG009)
Fonte
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0